ATAI - ATAI Life Sciences N.V.
IEX Last Trade
1.3
0 0%
Share volume: 394,716
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.30
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-15 | 2022-11-10 | 2023-03-24 | 2023-05-11 | 2023-08-10 | 2023-11-14 | 2024-03-28 | 2024-05-15 | |
| Assets | |||||||||
| Total Assets | 348.936 M | 342.597 M | 305.441 M | 280.717 M | 253.595 M | 308.220 M | 293.478 M | 269.121 M | |
| Current Assets | 323.608 M | 317.482 M | 287.145 M | 267.933 M | 242.770 M | 215.825 M | 185.592 M | 117.500 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 11.122 M | 13.425 M | 14.036 M | 9.199 M | 6.257 M | 6.831 M | 30.830 M | 5.732 M | |
| Short Term Investments | 11.122 M | 13.425 M | 14.036 M | 9.199 M | 6.257 M | 6.831 M | 30.830 M | 5.732 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 8.851 M | 9.021 M | 0.000 | 505.000 K | 522.000 K | |
| Current Cash | 312.486 M | 304.057 M | 273.109 M | 249.883 M | 227.492 M | 208.994 M | 154.257 M | 106.246 M | |
| Total Non-current Assets | 25.328 M | 25.115 M | 18.296 M | 12.784 M | 10.825 M | 92.395 M | 107.886 M | 151.621 M | |
| Property Plant Equipment | 303.000 K | 728.000 K | 928.000 K | 1.114 M | 1.043 M | 992.000 K | 981.000 K | 920.000 K | |
| Other Assets | 14.630 M | 15.889 M | 10.613 M | 5.824 M | 5.791 M | 16.233 M | 15.242 M | 17.689 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 348.936 M | 342.597 M | 305.441 M | 280.717 M | 253.595 M | 308.220 M | 293.478 M | 269.121 M | |
| Total liabilities | 37.261 M | 53.198 M | 44.701 M | 43.892 M | 41.045 M | 41.944 M | 50.516 M | 46.577 M | |
| Total current liabilities | 21.957 M | 25.913 M | 19.897 M | 19.953 M | 17.926 M | 19.695 M | 20.120 M | 15.013 M | |
| Accounts Payable | 2.738 M | 3.511 M | 2.399 M | 4.915 M | 3.859 M | 5.506 M | 4.589 M | 3.843 M | |
| Other liabilities | 6.238 M | 5.603 M | 4.661 M | 3.734 M | 3.649 M | 3.636 M | 13.831 M | 14.645 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 317.000 K | 322.000 K | 292.000 K | 0.000 | 244.000 K | |
| Long term debt | 619.000 K | 15.001 M | 15.117 M | 16.390 M | 16.383 M | 16.377 M | 15.211 M | 16.206 M | |
| Other liabilities | 6.238 M | 5.603 M | 4.661 M | 3.734 M | 3.649 M | 3.636 M | 13.831 M | 14.645 M | |
| Minority interest | 8.447 M | 6.681 M | 5.026 M | 3.815 M | 3.087 M | 2.236 M | 1.354 M | 713.000 K | |
| Total Shareholder equity | 311.675 M | 289.399 M | 260.740 M | 236.825 M | 212.550 M | 266.276 M | 242.962 M | 222.544 M | |
| Common stock | 153.971 M | 156.607 M | 158.770 M | 155.792 M | 155.792 M | 155.792 M | 167.958 M | 158.891 M | |
| Retained earnings | -431.290 M | -465.178 M | -510.188 M | -543.849 M | -576.891 M | -532.647 M | -550.938 M | -577.651 M |